A novel noninvasive multigene urine biomarker test for the surveillance of bladder cancer recurrence, The Cxbladder Monitor, offers high sensitivity and high negative predictive value for ruling out urothelial carcinoma. Results suggest potential for deferring or avoiding cystoscopy in bladder cancer patients.
A novel noninvasive multigene urine biomarker test for the surveillance of bladder cancer recurrence, The Cxbladder Monitor, offers high sensitivity and high negative predictive value for ruling out urothelial carcinoma. Results suggest potential for deferring or avoiding cystoscopy in bladder cancer patients.